Skip to main navigation
  • Contact Us linkedin
  • Homepage
  • About Us
    • Senior Leadership Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Our Platform
    • Publications & Presentations
  • Our Pipeline
    • Vilastobart (anti-CTLA-4)
    • Efarindodekin Alfa (IL-12)
    • XTX501
    • Masked T Cell Engagers
    • Expanded Access Policy
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Analyst Coverage
    • Investor FAQs
    • Email Alerts
    • Contact
  • Careers

SEC Filing Details

SEC Filing Details

Document Details

Form
10-K
Filing Date
March 23, 2026
Document Date
December 31, 2025
Form Description
Annual report which provides a comprehensive overview of the company for the past year
Filing Group
Annual Filings
Company
Xilio Therapeutics, Inc
Issuer
XILIO THERAPEUTICS, INC.

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
XML - XBRL INSTANCE DOCUMENT
Xilio Therapeutics, Inc logo

Xilio Therapeutics
828 Winter Street, Waltham, MA 02451

© 2026 Xilio Therapeutics, Inc.
All Rights Reserved

Privacy Policy

We use cookies to help personalize your experience. For more information on how we use cookies and similar technologies, and how you can change your settings, please see our Privacy Policy.
Cookie SettingsOk